Private · Company · Allmennaksjeselskap
Zelluna ASA
996 713 008 ↗Research and experimental development on natural sciences and engineering · NACE 72.100Oslo
↳ Brreg · companies
Parent of 1 companyZelluna Immunotherapy ASOperating at a lossFY2025 · -4560% margin
Activitylast 24 mo
No job-ad activity on file
totals on file · ads-over-time series not yet in Intelligo
Registry changes
No recorded changes.
NAV + JobStream · company_hiring · Brreg · company_changes
Timelineall sources
Going concernThe filing form states there is no uncertainty about going concern. — Er det usikkerhet om fortsatt drift?: NeiAnnual report · 2025-12-31
Going concernThe board states the current cash position is expected to fund planned operations into the first quarter of 2027. — support planned opera...Annual report · 2025-12-31
DividendNo dividend has historically been distributed and none is expected in the near future. — The Company has historically not distributed div...Annual report · 2025-12-31
DividendThe parent company's loss of MNOK 276.5 is transferred to share premium. — Zelluna ASA is transferred to Share Premium.Annual report · 2025-12-31
Staff numbersThe notes state man-years for the year (8.50 for the parent, 28.10 for the group). — Antall arsverk i regnskapsaretAnnual report · 2025-12-31
Staff numbersThe group had 24 employees at 31 December 2025 (24 FTEs). — As per 31 December 2025,the Group had 24 employees, of whomAnnual report · 2025-12-31
Related partyNotes disclose no loans or security provided to members of the board or other governing bodies (NOK 0). — Lan og sikkerhetsstillelse til ...Annual report · 2025-12-31
Share capitalThe AGM authorised a share capital increase of up to 20%, corresponding to up to NOK 4,045,413. — Company's share capital, corresponding ...Annual report · 2025-12-31
OwnershipZelluna ASA is a Norwegian public limited company listed on Euronext Oslo Børs. — Zelluna ASA is a Norwegian public limited liability com...Annual report · 2025-12-31
Sale processUltimovacs ASA completed a business combination with Zelluna on 3 March 2025, accounted for as a reverse acquisition with Zelluna Immunot...Annual report · 2025-12-31
ImpairmentGroup impairment of goodwill and intangible assets of MNOK 5.6 in 2025 (MNOK 2.3 IP licence, MNOK 3.2 goodwill). — Impairment of goodwill...Annual report · 2025-12-31
Post balance sheet eventThe board reports no significant events after the balance sheet date beyond those described under subsequent events. — There have been no...Annual report · 2025-12-31
RemunerationManagement had no bonus arrangements or separate cash incentive schemes in 2025; only a share option scheme approved by the general meeti...Annual report · 2025-12-31
Loan or financingTwo private placements were completed in 2025 with deviation from shareholders' pre-emption rights. — In 2025,the Company completed two p...Annual report · 2025-12-31
RestructuringFollowing negative phase II readouts, no further development of the UV1 cancer vaccine is planned and the programme is being concluded. —...Annual report · 2025-12-31
SubsidiaryThe parent balance sheet carries investment in subsidiary of NOK 294 140 000 at 31.12.2025. — Investering i datterselskapAnnual report · 2025-12-31
OtherDNB Bank ASA and Advokatfirmaet Schjødt AS were among the main suppliers/advisers due to the business combination and capital raises in 2...Annual report · 2025-12-31
GEVERAN TRADING COMPANY LTD acquired 9.5 pctNew owner · 2025-12-31
UBS SWITZERLAND AG acquired 5.6 pctNew owner · 2025-12-31
BIRK VENTURE AS acquired 5.7 pctNew owner · 2025-12-31
CANICA AS exited (held 7.9 pct)Owner exit · 2024-12-31
WATRIUM AS exited (held 5.2 pct)Owner exit · 2024-12-31
Skiwo · company_events
Job ads on NAV Arbeidsplassen12 MO
No job ads on record in the last 12 months.
NAV Arbeidsplassen · company_job_ad_months
LocationOslo
Oslo
municipality only · street address + coordinates not yet in Intelligo
Brreg · registered municipality